Shareholder Meeting Form 8 K

On June 26, 2024, MIRA Pharmaceuticals, Inc. (the "Company") entered into an Amended and Restated Employment Agreement (the "Amended and Restated Employment Agreement") that amends and restates the Employment Agreement, dated April 28, 2023, by and among the Company and Michelle Yanez, the Company's Chief Financial Officer. Pursuant to the Amended and Restated Employment Agreement, Ms. Yanez will continue to serve as the Company's Chief Financial Officer at a reduced annual base salary of $137,500. Ms. Yanez's previous annual base salary was $225,000.

The Amended and Restated Employment Agreement also provides that Ms. Yanez will use her reasonable best efforts to work a minimum of thirty (30) hours per week on Company matters, with the understanding that she shall have the ability to provide services to other companies owned and/or controlled by Bay Shore Trust and its affiliates, including Telomir Pharmaceuticals, Inc., where Ms. Yanez was appointed Chief Financial Officer on June 18, 2024.

The Amended and Restated Employment Agreement with Ms. Yanez is attached as Exhibit 10.1 to this Current Report on Form 8-K. The description of such agreement contained herein is summary in nature and is qualified in its entirety by reference to the full text of such agreement.